Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results for its Fovista drug. Fovista, working in tandem with Roche's (RHHBY.PK) Lucentis, treats a form of macular degeneration, and stands to compete with Regeneron's Eylea. Lucentis. Jefferies is defending Regeneron, arguing Fovista could just as well work in tandem with Eylea.
REGN—Where do you see any suggestion that Roche would seek to sell Fovista only in combination with Lucentis? Something like that has never been done with biologics, as far as I know, and it would encounter practical problems apart from the anti-competitive legal issues.
News 
Market Data 
Discover 
AI
